White House set to tout Medicaid ‘most favored nation’ drug pricing deals

The Trump administration is preparing to unveil a plan to extend "most favored nation" (MFN) drug pricing to Medicaid-covered medications across all 50 states, an administration official said. The president is expected to announce the policy on Friday in the Oval Office, joined by several governors.

According to the official, the MFN approach would affect some drugs paid for under Medicaid, though the announcement as reported did not specify which medicines or how many would be included. The administration frame positions the change as a response to concerns about prescription drug costs.

MFN pricing generally aims to tie domestic reimbursement rates to the lowest prices paid by comparable purchasers, often including international benchmarks. The administration’s statement, as described by the official, suggests a federal effort to leverage those pricing mechanisms within the Medicaid program.

The White House is emphasizing the announcement amid broader public attention to drug affordability. Details on implementation, timelines, and the specific drugs covered were not provided in the report and would be necessary to assess how the policy would operate across state Medicaid programs.